Widely read:
Anand Kumar/AI-Generated Image
Summary: Jubilant Ingrevia's revenue looks stuck in a rut. But underneath that flat line, the mix of the business has shifted quite dramatically, and a new bet is starting to take shape. Here's what the numbers reveal, and what's still standing in the way.
Chemicals doesn’t strike as a glamorous industry. Most companies make products in bulk, compete on prices and earn margins highly dependent on raw material costs.
And so, our aim was to find a company that went against the tide; someone that owns a niche few can enter, faces little direct competition and is transitioning into contract manufacturing rather than being a commodity producer. Only one name came up: Jubilant Ingrevia.
We then looked at the company’s revenue. Rs 4,949 crore in FY22. Rs 4,388 crore in FY26, four years later. The flat line hides two very different stories, and only one tells you what this business is becoming.
But first, let’s better understand what Jubilant Ingrevia does.
About the company
Jubilant Ingrevia’s largest business, at 44 per cent of revenue, is speciality chemicals. The anchor here is pyridine and its derivatives, used in herbicides, pesticides, anti-tuberculosis drugs and oil-well drilling fluids. Jubilant is one of the world's largest non-Chinese producers of these compounds, giving it real pricing leverage outside China. The segment also runs a contract manufacturing arm producing patented chemicals for global pharmaceutical and agrochemical companies.
Its second business, chemical intermediates at 38 per cent of revenue, is the older, more commoditised arm. Jubilant Ingrevia’s biggest product is acetic anhydride, a key ingredient used in the production of paracetamol, aspirin and ibuprofen at scale. Margins here track raw material costs closely.
The third business, nutrition and health solutions, is smaller but faster-growing. Jubilant is one of the largest producers of Vitamin B3, used in animal feed, food fortification and skincare.
Why Jubilant’s revenue went nowhere
|
|
FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue (Rs crore) | 4,388 | 4,178 | 4,136 | 4,773 | 4,949 |
| EBITDA margin (%) | 12.9 | 12.4 | 10.2 | 11.5 | 16.8 |
| EBITDA is earnings before interest, tax, depreciation and amortisation, excluding other income | |||||
Jubilant Ingrevia has been pushing higher volumes through the market. The issue? Prices fell faster than volumes grew, and one entire segment collapsed at the same time.
Chemical intermediates were hit hard when the Indian paracetamol supply chain destocked in FY24, cutting purchases by 20 to 25 per cent. Raw material costs also fell globally, and Jubilant had to pass the savings on to buyers, compressing realisations. The segment posted a 23 per cent revenue decline that year.
The nutrition segment faced a different force. Chinese manufacturers flooded global markets with Vitamin B3 at prices well below what others could match. For a company that exports more than 40 per cent of its production, that kind of price deflation drags down revenues.
Despite the hurdles, recovery seems to be in sight. Paracetamol destocking is in its late stages, and acetic acid pricing is firming as European supply disruptions redirect volumes to Jubilant. But two drags are structural and will not normalise. Global Vitamin B3 capacity is roughly twice non-Chinese demand, with Chinese producers on cost positions 40 to 60 per cent below Jubilant's. Pyridine faces a similar overhang, with Chinese capacity five to six times Jubilant's 50,000 tonnes. The uncomfortable part is that the cyclical recovery is showing up in the lowest-margin segment, while structural pressure sits in the higher-margin ones.
The real change happening inside
Below the flat revenue line, the mix of the business has shifted in a way that matters.
|
|
EBITDA margin (%) | Profit share (%) | ||
|---|---|---|---|---|
| Segment | FY24 | FY26 | FY24 | FY26 |
| Speciality chemicals | 16 | 26 | 48 | 75 |
| Nutrition and health | 9 | 13 | 12 | 15 |
| Chemical intermediates | 11 | 4 | 39 | 11 |
Chemical intermediates, once the largest earnings contributor, now generate just 11 per cent of Jubilant Ingrevia’s operating profit despite 38 per cent of revenue. Speciality chemicals has done the opposite, with its margin expanding from 16 to 26 per cent on better capacity utilisation and growing contract manufacturing work. Together, speciality and nutrition now generate roughly 90 per cent of operating profits on 62 per cent of revenue.
Rather than competing on volume in feed-grade Vitamin B3, where Chinese pricing is most punishing, Jubilant Ingrevia commissioned a plant for food-grade and cosmetic-grade niacinamide. These variants sell for 40 to 50 per cent more and face far less pressure from Chinese competitors. In speciality, the pull is increasingly from contract manufacturing rather than commodity pyridine.
What this does not do is make the structural overhang disappear. Jubilant Ingrevia has bought itself distance from the problem, not immunity to it.
But two drags are structural and will not normalise. First, global Vitamin B3 capacity is roughly twice non-Chinese demand, with Chinese producers on cost positions 40 to 60 per cent below Jubilant's. Pyridine faces a similar overhang, with Chinese capacity five to six times Jubilant's 50,000 tonnes. The uncomfortable part is that the cyclical recovery is showing up in the lowest-margin segment, while structural pressure sits in the higher-margin ones.
The contract manufacturing bet
The most important piece of the forward story is CDMO (contract development and manufacturing). A global pharma or agrochemical company appoints Jubilant to design the process, build the plant and make the compound. Once validated and written into regulatory approvals, switching suppliers means repeating years of compliance work. Margins typically run between 20 and 30 per cent.
The most significant contract, worth more than Rs 2,850 crore over five years with a take-or-pay structure that guarantees minimum volumes, is already dispatching products. A second agrochemical contract is in delivery. As of the most recent quarterly update, the confirmed pipeline stands at 25 molecules, up from 20 a quarter ago, carrying Rs 1,500 crore in confirmed peak revenue potential. The broader funnel runs to over 100 molecules and Rs 3,500 crore in total peak potential, though the five molecules added most recently are early-stage and their revenue contribution is not yet quantified. Seventy per cent of the pharma pipeline is non-pyridine, insulating this division from the Chinese competition that hits the core business.
What weighs on earnings now
Jubilant Ingrevia’s operating health has been improving, but reported earnings trail behind. Over three years, the company has invested Rs 1,745 crore in new capacity. Most plants run at 50 to 80 per cent utilisation, and the new acetic anhydride plant at just 30 to 35 per cent.
A plant below capacity carries nearly all its fixed costs and the full depreciation charge on money already spent, which is why profits have not caught up with operations. This is a timing gap, not a broken business. Management expects steady-state utilisation by FY27, after which incremental revenue should arrive at very little added cost. Further capital expenditure is planned from internal cash flows.
Management targets Rs 10,000-12,000 crore in revenue by FY30. The capex wave was originally expected to generate peak revenues in FY26 and has since slipped to FY27. Pricing remains the key variable. Much of the CDMO pharma pipeline is still in clinical trials, where delays are common. Even if CDMO hits its own Rs 2,000 crore revenue target, the remaining gap must come from segments that have not grown at that pace. The FY30 numbers are not impossible. They simply ask a great deal to go right at once.
The bottom line
Strip out the target and the flat top line, and what is left is a genuinely better company than its revenue suggests. The earnings base has moved toward speciality and nutrition, margins have expanded, and the CDMO franchise adds real optionality with genuine switching costs. That is the reason to be interested.
At 37 times earnings, though, the transformation is largely priced in. The case to act rather than watch requires three things: the new plants reaching steady-state utilisation on the FY27 timeline, CDMO converting from funnel to signed contracts, and pricing stabilising enough to keep the FY30 trajectory on track. Those are the triggers. Until they arrive, the price is ahead of the proof.
Should you invest in Jubilant Ingrevia?
Numbers on the surface, like a flat revenue line, rarely tell the full story. A business can be quietly transforming underneath, or it can be papering over real cracks. Telling the two apart takes a closer look at margins, segment mix and what management is actually doing with its capital, which is exactly what Value Research Stock Advisor helps you do. It offers in-depth, jargon-free research on individual stocks, so you can judge whether a company's story matches its numbers before you decide to invest.
Subscribe to Stock Advisor today
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
